|
Report No. : |
333118 |
|
Report Date : |
23.07.2015 |
IDENTIFICATION DETAILS
|
Name : |
VIMA PHARMA S A DE CV |
|
|
|
|
Registered Office : |
Av Rio Lerma No 32 Industrial Tlaxcoplan, Tlaxcoplantla de Baz CP 54030 |
|
|
|
|
Country : |
Mexico |
|
|
|
|
Year of Establishment : |
2009 |
|
|
|
|
Legal Form : |
Sociedad Anónima de Capital Variable |
|
|
|
|
Line of Business : |
Subject is dedicated to the import, marketing and distribution of raw materials
for the pharmaceutical industry. |
|
|
|
|
No. of Employees : |
4 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Mexico |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
MEXICO - ECONOMIC
OVERVIEW
Mexico's $1.3 trillion economy has become increasingly oriented
toward manufacturing in the 21 years since the North American Free Trade
Agreement (NAFTA) entered into force. Per capita income is roughly one-third
that of the US; income distribution remains highly unequal. Mexico has become
the United States' second-largest export market and third-largest source of
imports. In 2014, two-way trade in goods and services exceeded $550 billion.
Mexico has free trade agreements with 46 countries, putting more than 90% of
trade under free trade agreements. In 2012, Mexico formally joined the
Trans-Pacific Partnership negotiations and formed the Pacific Alliance with
Peru, Colombia and Chile. Mexico's current government, led by President Enrique
PENA NIETO, emphasized economic reforms during its first two years in office,
passing and implementing sweeping education, energy, financial, fiscal and
telecommunications reform legislation, among others, with the long-term aim to
improve competitiveness and economic growth across the Mexican economy.
Although the economy is expected to experience stronger growth in 2015 as a
result of increased investment and stronger demand for Mexican exports, growth
is predicted to remain below potential for reasons of inefficiencies, with a
large portion of the economy and workforce in the informal sector, and
corruption. Over the medium-term, the economy is vulnerable to global economic
pressures, such as lower external demand, rising interest rates, and low oil
prices - approximately 30% of government revenue comes from the state-owned oil
company, PEMEX. The increasing integration of supply chains, development of the
energy sector, and government-to-government focus on trade facilitation will
continue to make the North American region increasingly competitive and
contribute to Mexican economic development and strength.
|
Source
: CIA |
|
Order: |
Vima Pharma S A De CV |
|
Address in the order: |
Av Rio Lerma No 32 Industrial Tlaxcoplan, Tlaxcoplantla de Baz CP
54030, Mexico |
|
Legal Name: |
VIMA PHARMA SA DE CV |
|
Trade Name: |
VIMA PHARMA |
|
RFC: |
VPH090219R69 |
|
Date Created: |
2009 |
|
Date Incorporated: |
2009 |
|
Legal Address: |
Río Lerma No 32 Tlalnepantla de Baz, Estado de México 05430 México |
|
Operative Address: |
Río Lerma No 32 Tlalnepantla de Baz, Estado de México 05430 México |
|
Telephone: |
52 (55) 56114565 |
|
Fax: |
52 (55) 53842193 |
|
Legal Form: |
Sociedad Anónima de Capital Variable |
|
Email: |
|
|
Registered in: |
Mexico |
|
Website: |
|
|
Contact: |
Marco Tulio Morales, Director |
|
Staff: |
4 |
|
Activity: |
Pharmaceutical Industry |
|
BANK DATA |
BANAMEX |
|
|
|
|
|
The company does not disclose its banking information |
|
|
The company was established in 2009 |
|
|
|
|
PRINCIPAL ACTIVITY |
The company is dedicated to the import, marketing and distribution of raw
materials for the pharmaceutical industry. |
|
Products/Services description: |
Excipients, active pharmaceutical ingredients |
|
Brands: |
VIMA PHARMA INNOVACIÓN Y TECNOLOGÍA EN INGREDIENTES FARMACÉUTICOS |
|
Sales: |
Wholesale |
|
Clients: |
|
|
Suppliers: |
INDUKERN CHEMIE AG Switzerland India |
|
Operations area: |
National |
|
The company imports from |
India, Switzerland |
|
The company exports to |
No exports |
|
The subject employs |
4 employees |
|
Payments: |
Unknown |
|
Headquarters : |
Río Lerma No 32 Tlalnepantla de Baz, Estado de México 05430 México |
|
Branches: |
The company does not have branches |
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
This is a private company. It would be a subsidiary of: |
|
Management: |
Marco Tulio Morales, Director |
|
Related Companies: |
No subsidiary companies |
|
|
The company does not make its financial statements public. |
|
|
|
|
|
There are no financial connected to the subject |
|
|
There are no legal connected to the subject |
|
|
The company is dedicated to the import, marketing and distribution of
raw materials for the pharmaceutical industry. It has a small sized structure and 6 years of experience in the market. The company is controlled and operates at the same address than its
parent company Grupo Gylsa SA de CV. The company does not show any negative records, however; it has a low
commercial profile. |
|
DEBTS |
Controlled |
|
PAYMENTS |
Unknown |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
NAME |
Tatiana |
|
POSITION |
Administrative |
|
COMMENTS |
She confirmed RFC,
address, parent company. She refused to provide more information without knowing
the inquiring party. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.53 |
|
UK Pound |
1 |
Rs.99.19 |
|
Euro |
1 |
Rs.69.60 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.